In this article, we will look at the 8 Best Healthcare AI Stocks to Buy According to Analysts.
Healthcare AI stocks are getting more attention as investors look for places where artificial intelligence can move beyond chatbots and productivity tools into real-world markets. Healthcare is one of those areas where AI can touch drug discovery, diagnostics, medical imaging, clinical trials, hospital workflows, robotic surgery, and patient engagement. Janus Henderson frames the opportunity clearly, saying “AI is proving to have numerous applications in healthcare, from early detection of cancer to faster development of novel medicines.” The firm adds that these tools are “helping improve patient outcomes and creating efficiencies in the healthcare system,” which is why the theme is starting to matter for investors.
Capital Group says artificial intelligence is being used to “manage large data sets, improve clinical trial design and streamline operations,” while noting that “its operational benefits are becoming clearer.” This means that some of the nearer-term investment cases may come from less flashy areas like trial design, workflow automation, and cost efficiency.
That is why healthcare AI stocks deserve a closer look, especially those where the technology is tied to actual products, better clinical workflows, stronger data advantages, or clearer operating leverage. With that in mind, let’s take a look at the 8 Best Healthcare AI Stocks to Buy According to Analysts.
Our Methodology
We used the Finviz screener to identify healthcare AI stocks that offer upside of at least 25% based on analysts’ median price targets. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
8. SOPHiA GENETICS SA (NASDAQ:SOPH)
On April 15, 2026, BTIG raised its price target on SOPHiA GENETICS SA (NASDAQ:SOPH) to $8 from $7 and maintained a Buy rating. The firm said management “signaled confidence across the business” following investor meetings with President and incoming CEO Ross Muken, CFO George Cardoza, and Head of Strategy Kellen Sanger.
In March, SOPHiA GENETICS SA reported Q4 EPS of (28c) compared to (23c) a year earlier, while revenue rose to $21.7 million from $17.7 million. The company said performance was driven by 45% year-over-year growth in North America and 32% growth in the Asia Pacific. CEO Jurgi Camblong said the company finished 2025 with strong momentum, with Q4 revenue up 22% and full-year revenue increasing 19%.
For 2026, SOPHiA GENETICS expects revenue of $92 million to $94 million, above consensus estimates of $76.47 million, representing growth of about 20% to 22% year over year. The company also expects adjusted EBITDA in the range of ($29 million) to ($32 million).
SOPHiA GENETICS SA provides cloud-based software tools that help healthcare providers analyze complex clinical data and generate insights across multiple diagnostic platforms.
7. Certara, Inc. (NASDAQ:CERT)
On April 22, 2026, Certara, Inc. (NASDAQ:CERT) said it entered into a definitive agreement to sell its regulatory and medical writing business to Veristat for up to $135 million. The deal is expected to close in the second quarter of 2026, subject to customary conditions. The divested unit generated $50 million in revenue and $17 million in adjusted EBITDA in 2025 and includes about 220 employees. Certara said it plans to update its 2026 guidance after the transaction closes.
On April 13, 2026, KeyBanc analyst Scott Schoenhaus lowered his price target on Certara, Inc. to $8 from $10 while maintaining an Overweight rating. The firm said the near-term setup remains largely positive ahead of Q1 earnings, although it expects most companies to reaffirm full-year guidance given macro uncertainty. KeyBanc added that healthcare utilization trends remain solid, supporting software spending, even as pharma digital advertising conditions remain uneven.
In March, UBS lowered its price target on Certara, Inc. to $10 from $15 while maintaining a Buy rating. The firm said fourth-quarter results and 2026 guidance challenged the bullish thesis, citing a services miss and slower software bookings. Despite that, UBS said Certara remains “uniquely positioned” in model-informed drug development.
Certara, Inc. provides biosimulation software and services used in drug discovery, clinical development, regulatory submissions, and commercialization.
6. GE HealthCare Technologies Inc. (NASDAQ:GEHC)
On April 29, 2026, Stifel lowered its price target on GE HealthCare Technologies Inc. (NASDAQ:GEHC) to $80 from $98 while maintaining a Buy rating. The firm said the company’s Q1 report included a long list of positive business developments, but those were outweighed by rising inflationary pressures across multiple cost categories. Stifel estimates these pressures could create an incremental, roughly $250 million margin headwind in 2026. While management plans to offset part of the impact, the firm said most mitigation efforts will not fully materialize until the second half of the year, pointing to weaker-than-expected margins and EPS for 2026.
Citi also lowered its price target on GE HealthCare Technologies Inc. to $65 from $80 while maintaining a Neutral rating. The firm said expectations were already low heading into the print, but the company still missed and reduced its 2026 EPS guidance to $4.80 to $5.00 from $4.95 to $5.15, versus consensus of $5.06. Citi added that while the reset may help, the stock has now moved into a “show me” phase.
Earlier that same day, GE HealthCare reported Q1 adjusted EPS of $0.99, versus consensus of $1.05, while revenue of $5.1 billion came in slightly above expectations of $5.03 billion. CEO Peter Arduini said revenue landed at the high end of expectations, driven by strong execution in Pharmaceutical Diagnostics, including Flyrcado, along with Advanced Visualization Solutions, Imaging, and services. He noted that profitability was affected by a supplier issue in Pharmaceutical Diagnostics that has since been resolved, as well as higher costs for memory chips, oil, and freight, which are expected to persist through 2026.
GE HealthCare Technologies Inc. develops medical technologies, diagnostics, and digital solutions used in patient diagnosis, treatment, and monitoring globally.
5. AbCellera Biologics Inc. (NASDAQ:ABCL)
On April 22, 2026, JonesResearch highlighted AbCellera Biologics Inc. (NASDAQ:ABCL), noting that if its ABCL635 candidate demonstrates clean safety with no hepatic signals and achieves target engagement comparable to Veohah and Lynkuet, the therapy could be “very competitive.” The firm has reiterated its Buy rating and $11 price target on AbCellera Biologics Inc. ahead of a Phase 1 update expected on May 11, 2026.
Just earlier in the month of April, JonesResearch analyst Debanjana Chatterjee initiated coverage of AbCellera Biologics Inc. with a Buy rating and $11 price target on the shares. The firm has said that AbCellera Biologics Inc.’s antibody discovery platform has advanced 19 molecules into clinical development across both internal and partnered programs spanning multiple therapeutic areas, with its capabilities “best illustrated” through its collaboration with Eli Lilly.
AbCellera Biologics Inc. develops antibody-based therapies targeting diseases with unmet medical needs.
4. Butterfly Network, Inc. (NYSE:BFLY)
On April 30, 2026, Butterfly Network, Inc. (NYSE:BFLY) reported Q1 EPS of (3c), versus consensus estimates of (5c), while revenue rose to $26.5 million from expectations of $25.74 million. CEO Joseph DeVivo said the company delivered a strong start to the year, with 25% revenue growth and continued improvement in gross margins. He said the business is increasingly organized around three growth engines: global expansion of point-of-care ultrasound, the extension of those capabilities into Home & Community Care, and the growth of Butterfly Embedded, which expands the company’s technology beyond traditional ultrasound into new applications. He added that these initiatives are part of a single platform strategy that is beginning to scale.
Butterfly reaffirmed its full-year 2026 revenue guidance of $117 million to $121 million, compared with consensus estimates of $116.62 million, and continues to expect an adjusted EBITDA loss of $21 million to $25 million.
On April 21, 2026, the company appointed Arun Nagdev as Chief Medical Officer for Point-of-Care Ultrasound. In this role, he will lead global medical strategy for the company’s core POCUS business, including clinical validation, customer engagement, and regulatory development. He currently serves as Director of Emergency Ultrasound at Highland General Hospital and as an Associate Clinical Professor at the University of California, San Francisco.
Butterfly Network, Inc. develops handheld ultrasound imaging systems, including its Butterfly iQ+ and iQ3 devices, designed to deliver whole-body imaging through a single probe integrated with mobile and hospital-based workflows.
3. Medtronic plc (NYSE:MDT)
On April 26, 2026, Medtronic announced continued momentum for the Affera family of technologies for cardiac arrhythmia treatment, including promising data presented at the Heart Rhythm Society (HRS) Annual Meeting and the start of a new trial to evaluate a broader population of atrial fibrillation (Afib) patients. Results from the ongoing early feasibility study evaluating the Affera mapping and ablation system and the Sphere-9 catheter for treatment of recurrent sustained monomorphic ventricular tachycardia after a heart attack were presented as a late-breaking clinical trial. Patients treated at centers across the U.S. were followed for six months post-ablation. Results showed 65.5% of patients remaining free from VT recurrence at six months. The U.S. Food and Drug Administration granted Breakthrough Device Designation for the Sphere-9 catheter for the treatment of VT, providing an expedited regulatory pathway for the technology.
At HRS, a new sub-analysis from the Sphere-360 European study demonstrated positive results related to the durability of lesions in AFib procedures in patients with left common pulmonary veins. Results showed 100% lesion durability, highlighting consistency across patients with varied anatomies. Medtronic also announced the first patient enrollment in Conquer-AF, a prospective, multi-center, interventional, non-randomized study to characterize the safety and effectiveness of the Sphere-9 catheter in patients with recurrent paroxysmal or persistent AFib who have previously had an ablation procedure.
On April 23, 2026, Jefferies analyst Matthew Taylor lowered the firm’s price target on Medtronic (MDT) to $95 from $108 and kept a Hold rating on the shares. The firm updated its FY26 EPS outlook to reflect MiniMed (MMED) IPO timing and one-time expenses for MiniMed Flex. Jefferies added that Medtronic’s announced one-time $157M charge in Q4 related to the present value of future payments owed to Blackstone for the MiniMed Flex launch added to the EPS guide revision.
Medtronic plc (NYSE:MDT) develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.
2. Waystar Holding Corp. (NASDAQ:WAY)
On April 29, 2026, Waystar Holding Corp. (NASDAQ:WAY) reported Q1 adjusted EPS of $0.42, ahead of consensus estimates of $0.39, while revenue came in at $313.9 million versus expectations of $311.68 million. CEO Matt Hawkins said the company delivered a solid start to the year, supported by strong execution and continued platform expansion. He noted progress on the Iodine integration, the launch of new offerings including an AI-powered recoupment solution, and bookings that exceeded internal expectations as more healthcare providers standardize on Waystar’s platform.
Waystar reaffirmed its fiscal 2026 outlook, guiding for adjusted EPS of $1.59 to $1.68 compared with consensus estimates of $1.63, and revenue of $1.274 billion to $1.294 billion versus expectations of $1.29 billion.
Following the report, UBS analyst Kevin Caliendo lowered his price target on Waystar Holding Corp. to $37 from $41 while maintaining a Buy rating. The firm said the company posted solid results, with both total and subscription revenue exceeding expectations and EBITDA margins coming in above prior levels and long-term targets, signaling strong underlying profitability. However, UBS noted that unchanged full-year guidance and a slightly softer near-term growth cadence could weigh on sentiment, especially given the company’s history of raising expectations throughout the year.
Waystar Holding Corp. provides cloud-based software solutions that help healthcare providers manage payments, claims, and revenue cycle operations.
1. Intuitive Surgical, Inc. (NASDAQ:ISRG)
On April 23, 2026, Barclays lowered its price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $651 from $712 while maintaining an Overweight rating following the company’s Q1 results. The firm said the quarter delivered a “strong fundamental beat,” driven by procedure growth and system placements.
A day earlier, Baird raised its price target on Intuitive Surgical, Inc. to $610 from $575 and kept an Outperform rating. The firm updated its model after the company’s beat-and-raise quarter, though it cautioned that broader MedTech sentiment could weigh on the stock.
On April 21, 2026, Intuitive Surgical reported Q1 adjusted EPS of $2.50, well above consensus estimates of $2.11, while revenue rose to $2.77 billion from expectations of $2.62 billion. Worldwide procedures across the da Vinci Surgical System and Ion System platforms grew about 17% year over year. Da Vinci procedures increased approximately 16%, while Ion procedures rose around 39%. The company placed 431 da Vinci systems during the quarter, up from 367 a year earlier, including 232 da Vinci 5 systems compared to 147 in the prior-year period. It also placed 52 Ion systems, up from 49 last year.
For full-year 2026, Intuitive Surgical expects da Vinci procedure growth of about 13.5% to 15.5%, a non-GAAP gross margin of 67.5% to 68.5% of revenue, and operating expense growth of 11% to 14%. The margin outlook includes an estimated 1% revenue impact from tariffs.
Intuitive Surgical, Inc. develops robotic-assisted surgical systems and related technologies aimed at expanding access to minimally invasive care globally.
READ NEXT: 8 Best Beginner Stocks to Buy Right Now and 10 Fastest-Growing Financial Stocks to Invest In
Hedge Fund Resource Center